9.50

0.74% 0.07

After Hours: 9.35 -0.15 -1.58%

Zevra Therapeutics Inc (ZVRA)

Overview News Price History Option Chain Discussions Forecast Stock Split

Zevra Therapeutics Inc stock is traded at $9.50, with a volume of 385.40K. It is up +0.74% in the last 24 hours and up +22.58% over the past month. Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Previous Close:

$9.43

Open:

$9.51

24h Volume:

385.40K

Relative Volume:

0.45

Market Cap:

$508.14M

Revenue:

$27.46M

Net Income/Loss:

$-46.05M

P/E Ratio:

-10.11

EPS:

-0.94

Net Cash Flow:

$-33.83M

1W Performance:

+5.91%

1M Performance:

+22.58%

6M Performance:

+103.86%

1Y Performance:

+93.88%

1-Day Range:

$9.39

$9.66

1-Week Range:

$8.90

$9.76

52-Week Range:

$4.20

$9.76

Zevra Therapeutics Inc Stock (ZVRA) Company Profile

Name

Zevra Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(321) 939-3416

Address

1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

ZVRA's Discussions on Twitter

Compare ZVRA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZVRA Zevra Therapeutics Inc	9.50	508.14M	27.46M	-46.05M	-33.83M	-0.94
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-07-24	Initiated	Guggenheim	Buy
Sep-24-24	Initiated	JMP Securities	Mkt Outperform
Sep-24-24	Reiterated	Maxim Group	Buy
Apr-02-24	Reiterated	Maxim Group	Buy
Mar-12-24	Initiated	William Blair	Outperform
Mar-17-23	Initiated	Maxim Group	Buy

View All

Zevra Therapeutics Inc Stock (ZVRA) Latest News

Nov 26, 2024

Propel Bio Management LLC Invests $1.25 Million in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat

Nov 26, 2024

Zevra Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times

Nov 26, 2024

Zevra Therapeutics CEO to Present at Major Healthcare Investment Conferences | ZVRA Stock News - StockTitan

Nov 26, 2024

Nov 25, 2024

Zevra Therapeutics' SWOT analysis: rare disease drug maker's stock poised for growth - Investing.com

Nov 25, 2024

Nov 23, 2024

Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 52-Week HighShould You Buy? - MarketBeat

Nov 23, 2024

Zevra launches first FDA-approved NPC treatment By Investing.com - Investing.com Australia

Nov 22, 2024

Nov 21, 2024

Zevra launches first FDA-approved NPC treatment - Investing.com India

Nov 21, 2024

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C - Yahoo Finance

Nov 21, 2024

HC Wainwright Has Negative Forecast for ZVRA FY2028 Earnings - MarketBeat

Nov 21, 2024

Nov 20, 2024

Zevra Therapeutics (NASDAQ:ZVRA) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 20, 2024

Guggenheim Initiates Coverage of Zevra Therapeutics (ZVRA) with Buy Recommendation - MSN

Nov 20, 2024

Zevra Therapeutics (STU:1GDA) Enterprise Value : €424.12 Mil (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024

Zevra Therapeutics Q3 2024 Earnings Preview - MSN

Nov 20, 2024

Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 20, 2024

Nov 18, 2024

(ZVRA) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 18, 2024

What is William Blair's Forecast for ZVRA FY2024 Earnings? - MarketBeat

Nov 18, 2024

Cantor Fitzgerald Issues Negative Estimate for ZVRA Earnings - MarketBeat

Nov 18, 2024

Nov 16, 2024

Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report - Yahoo Finance

Nov 16, 2024

Nov 15, 2024

Zevra testing beta blocker celiprolol for vEDS in Phase 3 US study - Ehlers-Danlos News

Nov 15, 2024

Simplify Asset Management Inc. Invests $833,000 in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat

Nov 15, 2024

What is William Blair's Estimate for ZVRA FY2026 Earnings? - MarketBeat

Nov 15, 2024

Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results - Simply Wall St

Nov 15, 2024

Roth Capital Forecasts Lower Earnings for Zevra Therapeutics - MarketBeat

Nov 15, 2024

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Sees Large Decline in Short Interest - MarketBeat

Nov 15, 2024

Nov 14, 2024

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 14, 2024

Earnings call: Zevra Therapeutics reports Q3 financial results - Investing.com

Nov 14, 2024

Canaccord Genuity Group Issues Pessimistic Forecast for Zevra Therapeutics (NASDAQ:ZVRA) Stock Price - MarketBeat

Nov 14, 2024

Q4 Earnings Forecast for ZVRA Issued By Roth Capital - MarketBeat

Nov 14, 2024

Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 14, 2024

Nov 13, 2024

Janney Montgomery Scott LLC Sells 127,755 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat

Nov 13, 2024